Healthcare
PAI to acquire Amplitude from Apax
Apax, which currently owns 41.4% of the listed company, would fully exit its stake
Fund+ leads €23m series-A for Exevir
Exevir will commit to the international effort to pursue new treatment for Covid-19
Life Science Partners et. al in series-A round for Vico Therapeutics
Biotech startup will use the proceeds to further advance its therapy
Eurazeo China Acceleration Fund invests €80m in DORC
This is the first deal made by the fund, which targets companies with high-growth potential in the Chinese market
Consortium in $60m series-B for Withings
Withings plans to add 100 new positions in the US and France by the end of the year to strengthen its teams
Sofinnova, AbbVie lead €28m series-A for Enthera
Indaco Venture Partners, JDRF T1D Fund and several Italian investors also take part in the round
IK sells Aposan to Ardian-backed Santé Cie
Sale ends an investment period of almost four years, during which revenues and EBITDA doubled
Advent France Biotechnology, Invivo invest €4.25m in Arthex
Company intends to use the fresh capital to advance the development of its myotonic dystrophy therapy
Fund+ leads €38m series-B for Indigo Diabetes
Jan Van den Bossche, partner at Fund+, will join the board of the company
Capiton buys CNP Group
Acquisition of the pharmaceutical company marks the first deal from Capiton's sixth fund
QIA et al. invest $162m in CureVac
mRNA vaccine developer is valued at $1.6bn and also secured backing from the KfW and GlaxoSmithKline
BioMed Partners and HTGF lead €10.7m round for Tubulis
Seventure Partners, Coparion, Bayern Kapital and Occident also back the pharmaceutical company
BIVF et al. back CHF 25m round for T3 Pharmaceuticals
Reference Capital and multi-family office Wille Finance also backed the cancer therapy developer
CVC buys Italian pharma company Genetic
GP deploys capital from CVC Strategic Opportunities II, which held a final close on €4.6bn in July 2019
Auctus-backed PharmaLex buys Regulis Consulting
Deal is the consultancy's second bolt-on in 2020; it expects to generate 2020 revenues of €120m
Cathay Capital leads €30m round for Biose
Company intends to use the fresh capital to strengthen its market position, and expand in the US and China
Novo Holdings et al. in $20m round for Reapplix
Company will use the proceeds to commercialise its flagship product across the US
Elige Capital, Extens invest in Medireport
Company intends to use the fresh capital to consolidate its market position in France and boost its expansion
Kester-backed Frontier sells business to HIG-backed Vernacare
HIG invested from its Growth Buyout Equity Fund III to acquire Vernacare from Palatine
Blackstone Life Sciences V closes on $4.6bn
Fund invests in late-stage rounds of established life science companies and emerging businesses
Great Point's MLM Medical Labs buys CirQuest
Acquisition of US-based laboratory services provider is part of MLM's international expansion strategy
Mercia sells NAC to PE-backed LGC for £18m
Mercia held a 29.4% stake in NAC at the date of sale and will receive initial cash proceeds of ТЃ4.8m
Forbion holds first close for Growth Opportunities Fund
New strategy focuses on pre-IPO capital and capital for undervalued listed life sciences companies
Osivax raises €33m from EIC and BPI France
Of the funding, €15m from EIC will count towards series-B funding, while the rest will be a grant